Analyst Price Targets — TRDA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 10, 2026 9:19 pm | — | Guggenheim | $20.00 | $10.82 | TheFly | Entrada Therapeutics initiated with a Buy at Guggenheim |
| January 28, 2026 12:34 pm | Kostas Biliouris | Oppenheimer | $21.00 | $11.00 | TheFly | Entrada Therapeutics initiated with an Outperform at Oppenheimer |
| November 6, 2025 11:37 pm | — | Roth Capital | $13.00 | $6.95 | TheFly | Entrada Therapeutics price target lowered to $13 from $17 at Roth Capital |
| February 28, 2025 1:18 pm | — | Roth Capital | $23.00 | $11.94 | TheFly | Entrada Therapeutics price target lowered to $23 from $29 at Roth MKM |
| November 6, 2024 11:41 am | Boobalan Pachaiyappan | H.C. Wainwright | $20.00 | $18.03 | StreetInsider | Entrada Therapeutics (TRDA) PT Raised to $20 at H.C. Wainwright |
| June 25, 2024 6:24 am | Raghuram Selvaraju | H.C. Wainwright | $18.00 | $14.24 | TheFly | Entrada Therapeutics price target lowered to $18 from $20 at H.C. Wainwright |
Latest News for TRDA
BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 12,990 restricted stock units (“RSUs”) to two newly-hired non-executive employees under the Company's 2025 Inducement Equity Plan (the “Inducement Plan”), effective as of March 1, 2026. The inducement grants were previously approved by the Compensation Committee of the…
– Company on track to report ELEVATE-44-201 data from Cohort 1 in Q2 2026 and Cohort 2 by year-end 2026 – – Company on track to report ELEVATE-45-201 data from Cohort 1 in mid-2026 – – Independent Data Monitoring Committee recommended initiation of Cohort 2 at the increased dose of 12 mg/kg in the ELEVATE-44-201 study – – Cash runway expected into Q3 2027 with $ 296 million in cash, cash equivalents and marketable…
Entrada Therapeutics (TRDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
-- Patients in Cohort 1 have progressed to the open label, Phase 2 portion of ELEVATE-44-201 -- -- Company on track to report ELEVATE-44-201 Cohort 1 data in Q2 2026, with Cohort 2 data by end of year -- BOSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK…
Entrada Therapeutics (NASDAQ: TRDA) used a presentation at Guggenheim's 2026 Emerging Outlook Biotech Summit to outline its pipeline focus on intracellular therapeutics and to preview multiple clinical data catalysts expected in 2026, particularly in Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). Company focus and platform CEO Dipal Doshi described Entrada as a Boston-based
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TRDA.
U.S. House Trading
No House trades found for TRDA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.